How to take Gilteritinib

Gilteritinib (Gilteritinib) is a treatment for adult patients with relapsed or refractory acute myeloid leukemia (AML) who have FMS-like tyrosine kinase 3 (FLT3) mutations. Its use must follow specific usage and dosage guidelines to ensure efficacy and safety.

Before treatment, doctors need to decide whether to use giritinib based on the test results of FLT3 mutations in the patient's blood or bone marrow. Before starting treatment, the patient's blood counts and blood chemistry, including creatine phosphokinase levels, must be assessed. Frequency of assessments is weekly for the first month, every other week for the second month, and monthly thereafter during treatment. In addition, electrocardiograms (ECG) are performed on days 8 and 15 of cycle 1, and before the start of the next two cycles, to monitor the patient's heart health.

Regarding recommended dosage, the starting dose of gilitinib is 120 mg once dailywith or without meals. It should be noted that patients may not see immediate effects in the early stages of treatment, so it is recommended to continue treatment for at least 6 months without disease progression or unacceptable toxic reactions to allow sufficient time to observe clinical responses.

In terms of medication management, gilitinib tablets must not be broken or crushed and must be taken orally at approximately the same time every day according to the instructions. If the patient misses a dose, he or she should take it as soon as possible on the same day, but at least 12 hours before the next scheduled dose. If the missed dose occurs on the same day, the two doses should not be repeated within 12 hours and the normal dosing schedule should be resumed the next day. Through such management, patients can be helped to better follow the treatment plan, improve treatment effectiveness, and reduce the risk of side effects.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5ff59aa-9c0d-49a8-9053-1f179b482383